Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.37 |
| ▸ | GBA1 | P04062 | 3/20 | 0.37 |
| ▸ | GANAB | Q14697 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15072039 | 1.00 | THRB (0.38) | THRBLMNASPHK2SPHK1GBA1 | |
| SCHEMBL12838262 | 1.00 | THRB (0.38) | THRBLMNASPHK2SPHK1GBA1 | |
| SCHEMBL15623379 | 1.00 | THRB (0.38) | THRBLMNASPHK2SPHK1GBA1 | |
| SCHEMBL11083697 | 1.00 | THRB (0.38) | THRBLMNASPHK2SPHK1GBA1 | |
| SCHEMBL14410884 | 1.00 | THRB (0.38) | THRBLMNASPHK2SPHK1GBA1 | |
| SCHEMBL23988570 | 1.00 | THRB (0.38) | THRBLMNASPHK2SPHK1GBA1 | |
| SCHEMBL13082871 | 1.00 | THRB (0.38) | THRBLMNASPHK2SPHK1GBA1 | |
| SCHEMBL17779781 | 1.00 | THRB (0.38) | THRBLMNASPHK2SPHK1GBA1 | |
| SCHEMBL21095378 | 1.00 | THRB (0.38) | THRBLMNASPHK2SPHK1GBA1 | |
| SCHEMBL19782036 | 1.00 | THRB (0.38) | THRBLMNASPHK2SPHK1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365610-A1 | Aryl Glucoside Derivative | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20180016291-A1 | Rebaudioside Analogs | PEPSICO, INC. | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016291-A1 | Rebaudioside Analogs | SLC5A1, TAS1R1, FBP1 | THRB 3312/4885LMNA 4015/4885SPHK2 1500/4885 |
| US-20230365610-A1 | Aryl Glucoside Derivative | SLC5A1, SLC5A2, SLC10A1 | THRB 1608/4885LMNA 3998/4885SPHK2 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.